ABRAMS'6CLINICAL6DRUG6THERAPY:6RATIONALES6FOR6NURSING6PRACTICE
,ABRAMS'6CLINICAL6DRUG6THERAPY:6RATIONALES6FOR6NURSING6PRACTICE
,ABRAMS'6CLINICAL6DRUG6THERAPY:6RATIONALES6FOR6NURSING6PRACTICE
, ABRAMS'6CLINICAL6DRUG6THERAPY:6RATIONALES6FOR6NURSING6PRACTICE
Chapter 1, The Foundation of Pharmacology: Quality and Safety
6 6 6 6 6 6 6 6
1. A6woman6diagnosed6with6obsessive–
compulsive6disorder6has6been6prescribed6oral6paroxetine6hydrochloride.6What6is6the
6expected6effect6for6this6prescription?
A. Curative6effect6on6symptoms
B. Systemic6effect6on6symptoms
C. Local6effect6on6symptoms
D. Parenteral6effect6on6symptoms
ANS:6 B
Rationale:6Drugs6that6produce6systemic6effects6are6taken6into6the6body,6circulated6through6th
e6bloodstream6to6their6sites6of6action6in6various6body6tissues,6and6eventually6eliminated6from6
the6body.6Curative6agents6are6given6to6cure6a6disease6process.6In6this6case,6paroxetine6hydroc
hloride6will6control6the6symptoms6but6not6cure6the6disorder.6Drugs6with6local6effects,6such6as6
sunscreen6and6local6anesthetics,6act6mainly6at6the6site6of6application.6Paroxetine6hydrochlori
de6is6not6administered6parenterally.6Parenteral6agents6are6administered6subcutaneously,6intra
muscularly,6or6intravenously.
PTS: 1 REF: p.63,6Introduction OBJ: 1
NAT:6 Client6Needs:6Physiological6Integrity:6Pharmacological6and6Parenteral6Therapies6
TOP: Chapter:61:6The6Foundation6of6Pharmacology:6Quality6and6Safety
KEY:6 Integrated6Process:6Nursing6Process
BLM:6 Cognitive6Level:6Understand NOT:6 Multiple6Choice
2. A6client6has6been6prescribed6an6antibiotic.6This6medication6is6a6naturally6occurring
substance6that6has6been6cheG
mRicA
alDlyEm
SoBdOifOieSd.TWhaOt6M
.C is6another6name6for6this6type6of6medi
cation?
A. Synthetic6drug
B. Semisynthetic6drug
C. Biotechnology6drug
D. Prototype6drug
ANS:6 B
Rationale:6Semisynthetic6drugs6(e.g.,6many6antibiotics)6are6naturally6occurring6substances6tha
t6have6been6chemically6modified.6Synthetic6drugs6are6more6standardized6in6their6chemical6char
acteristics,6more6consistent6in6their6effects,6and6less6likely6to6produce6allergic6reactions.6Biote
chnology6drugs6involve6manipulating6DNA6and6RNA6and6recombining6genes6into6hybrid6mol
ecules6that6can6be6inserted6into6living6organisms.6Prototype6drugs6are6the6first6drug6of6a6partic
ular6group6to6be6developed.
PTS: 1 REF: p.63,6Drug6Sources OBJ: 1
NAT:6 Client6Needs:6Physiological6Integrity:6Pharmacological6and6Parenteral6Therapies6
TOP: Chapter:61:6The6Foundation6of6Pharmacology:6Quality6and6Safety
KEY:6 Integrated6Process:6Nursing6Process
BLM:6 Cognitive6Level:6Understand NOT:6 Multiple6Choice
3. Which6classification6applies6to6morphine?
A. Central6nervous6system6depressant
B. Central6nervous6system6stimulant
ABRAMS'6CLINICAL6DRUG6THERAPY:6RATIONALES6FOR6NURSING6PRACTICE
,ABRAMS'6CLINICAL6DRUG6THERAPY:6RATIONALES6FOR6NURSING6PRACTICE
,ABRAMS'6CLINICAL6DRUG6THERAPY:6RATIONALES6FOR6NURSING6PRACTICE
, ABRAMS'6CLINICAL6DRUG6THERAPY:6RATIONALES6FOR6NURSING6PRACTICE
Chapter 1, The Foundation of Pharmacology: Quality and Safety
6 6 6 6 6 6 6 6
1. A6woman6diagnosed6with6obsessive–
compulsive6disorder6has6been6prescribed6oral6paroxetine6hydrochloride.6What6is6the
6expected6effect6for6this6prescription?
A. Curative6effect6on6symptoms
B. Systemic6effect6on6symptoms
C. Local6effect6on6symptoms
D. Parenteral6effect6on6symptoms
ANS:6 B
Rationale:6Drugs6that6produce6systemic6effects6are6taken6into6the6body,6circulated6through6th
e6bloodstream6to6their6sites6of6action6in6various6body6tissues,6and6eventually6eliminated6from6
the6body.6Curative6agents6are6given6to6cure6a6disease6process.6In6this6case,6paroxetine6hydroc
hloride6will6control6the6symptoms6but6not6cure6the6disorder.6Drugs6with6local6effects,6such6as6
sunscreen6and6local6anesthetics,6act6mainly6at6the6site6of6application.6Paroxetine6hydrochlori
de6is6not6administered6parenterally.6Parenteral6agents6are6administered6subcutaneously,6intra
muscularly,6or6intravenously.
PTS: 1 REF: p.63,6Introduction OBJ: 1
NAT:6 Client6Needs:6Physiological6Integrity:6Pharmacological6and6Parenteral6Therapies6
TOP: Chapter:61:6The6Foundation6of6Pharmacology:6Quality6and6Safety
KEY:6 Integrated6Process:6Nursing6Process
BLM:6 Cognitive6Level:6Understand NOT:6 Multiple6Choice
2. A6client6has6been6prescribed6an6antibiotic.6This6medication6is6a6naturally6occurring
substance6that6has6been6cheG
mRicA
alDlyEm
SoBdOifOieSd.TWhaOt6M
.C is6another6name6for6this6type6of6medi
cation?
A. Synthetic6drug
B. Semisynthetic6drug
C. Biotechnology6drug
D. Prototype6drug
ANS:6 B
Rationale:6Semisynthetic6drugs6(e.g.,6many6antibiotics)6are6naturally6occurring6substances6tha
t6have6been6chemically6modified.6Synthetic6drugs6are6more6standardized6in6their6chemical6char
acteristics,6more6consistent6in6their6effects,6and6less6likely6to6produce6allergic6reactions.6Biote
chnology6drugs6involve6manipulating6DNA6and6RNA6and6recombining6genes6into6hybrid6mol
ecules6that6can6be6inserted6into6living6organisms.6Prototype6drugs6are6the6first6drug6of6a6partic
ular6group6to6be6developed.
PTS: 1 REF: p.63,6Drug6Sources OBJ: 1
NAT:6 Client6Needs:6Physiological6Integrity:6Pharmacological6and6Parenteral6Therapies6
TOP: Chapter:61:6The6Foundation6of6Pharmacology:6Quality6and6Safety
KEY:6 Integrated6Process:6Nursing6Process
BLM:6 Cognitive6Level:6Understand NOT:6 Multiple6Choice
3. Which6classification6applies6to6morphine?
A. Central6nervous6system6depressant
B. Central6nervous6system6stimulant
ABRAMS'6CLINICAL6DRUG6THERAPY:6RATIONALES6FOR6NURSING6PRACTICE
